Revisiting the Correlate of Reduced HIV Infection Risk in the Rv144 Vaccine Trial

Susan Zolla‐Pazner, Peter B. GilbertJournal of Virology 2019 · DOI

Abstract

The RV144 vaccine trial is the only clinical study to have shown a modest but statistically significant decrease in HIV infection risk. RV144 and the subsequent studies identifying the level of V1V2-specific antibodies as a correlate of reduced infection risk are still controversial despite many papers supporting and expanding the initial study. We address these controversies and summarize active-immunization and passive-immunization experiments in nonhuman primates that support the initial finding.
BibTeX
@article{zollapazner2019revisiting,
  author = {Susan Zolla‐Pazner and Peter B. Gilbert},
  title = {{Revisiting the Correlate of Reduced HIV Infection Risk in the Rv144 Vaccine Trial}},
  journal = {Journal of Virology},
  year = {2019},
  doi = {10.1128/jvi.00629-19},
}

Loading related content...

Figure